Protect ME - Practice Policy
1. Identify common clinical scenarios
2. Formulate protocols for FIRST LINE and ALTERNATIVE antimicrobial therapy for these conditions
3. Consider appropriate antimicrobial dosing using an evidence based approach
4. Classify key antibiotics as PROTECTED or AVOIDED
Identify common clinical presentations and suggest first line and alternative drugs for empirical treatment of these conditions using the BEVA antimicrobial policy template document as an example. *NEW for 2016*
The document is by no means presented as the ‘ideal antimicrobial policy’. It is an example that you can change and amend as appropriate. Where members choose to, they may share their own version of this document with BEVA via the submit button in the hope that consensus can be achieved for a least some of these clinical conditions.
Evidence for empirical and prophylactic antimicrobial use can be found in our journals
To access full text of EVJ and EVE articles you should login as a BEVA Member
Classify key antibiotics as PROTECTED or AVOIDED
PROTECTED ANTIBIOTICS should include
The 3rd and 4th Generation cephalosporins (eg Ceftiofur and cefquinome)
Fluoroquinolones (eg enrofloxacin)
Macrolides (eg Azithromycin).
These drugs should not be used empircally as first line medicines.
AVOIDED antimicrobials are defined as those which should not be used within your practice and include vancomycin and the carbapenems. You may consider other drugs in this category. Educate your staff to ensure that no orders are placed for drugs in this category.
Formulate a policy whereby PROTECTED antimicrobials can be used with certain safeguards using the BEVA Use of protected antimicrobials policy document as an example.